This month, we want to share the acknowledgment that APICES has received in the recent publication titled “A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial”. published in European Journal of Cancer in which APICES has collaborated in all phases of the project as design, setup, coordination and project management, data management, statistical analysis, abstract, poster and manuscript preparation. This means an extra motivation to all APICES team in order to give continuity to the implication we have in every project in which we collaborate. APICES is very proud of the recognition of our work, and we would like to thank Miguel A. Climent and Spanish Oncology Genitourinary Group (SOGUG) for giving us the opportunity to appear in the acknowledgements of the publication and congratulate them and all the investigators for their project success.
This study evaluates the efficacy and safety of maintaining or withdrawing abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer who had experienced cancer progression to this treatment and were beginning docetaxel therapy.
You can find the publication in the following link:
https://www.sciencedirect.com/science/article/pii/S0959804922004671
